703 results about "Ulcerative colitis" patented technology

The invention provides application of polygonatum cyrtonema polysaccharide in preparation of medicines for treating ulcerative colitis or reducing blood glucose. A main chain of a sugar chain structure of the homogeneous polysaccharide PCP2 in polygonatum cyrtonema is mainly composed of-> 1)-beta-D-Fur-(2->,-> 1, 6)-beta-D-Fur-(2-> and-> 6)-alpha-D-Glcp-(1-> and beta-D-Fur-(2->), a side chain is mainly composed of beta-D-Fur-(2-> and-> 2)-beta-D-Fur-(6-> at a C-6 position of-> 1, 6)-beta-D-Fur-(2->), Fur represents furanose, Glcp represents glucopyranose, Glcp represents glucopyranose, and Glcp represents glucopyranose. The novel polysaccharide compound can relieve intestinal injury of mice, increase expression of tight nectin and mucoprotein, relieve oxidative stress reaction, promote production of short-chain fatty acid and improve composition of intestinal flora, and can be applied to the field of medicine as a medicine for treating ulcerative colitis. Meanwhile, the homogeneous polysaccharide PCP2 in polygonatum cyrtonema can significantly inhibit the activity of alpha-amylase and alpha-glucosidase, can also promote the ability of insulin resistance 3T3-L1 fat cells to uptake and consume glucose, shows a significant hypoglycemic effect, and has a good development prospect in the aspect of preparation of hypoglycemic drugs.

The invention belongs to the field of new application of medicines, and particularly relates to gastrodia elata polysaccharide and application thereof. The gastrodia elata polysaccharide component GEP-2 is separated from crude gastrodia elata polysaccharide, structural characterization detection is conducted on the GEP-2, the result shows that the gastrodia elata polysaccharide GEP-2 is prepared from, by mass, 89.08% of glucose, 2.40% of galactose, 7.12% of galacturonic acid, 0.86% of arabinose and 0.54% of rhamnose, and the animal experiment result shows that the GEP-2 relieves the symptoms of mouse colitis, relieves weight loss and shortens the colon length; the traditional Chinese medicine composition has the advantages of reducing serum TNF-alpha, IL-1beta and IL-6 proinflammatory cytokine levels, improving the intestinal barrier function, reducing inflammatory cell infiltration, regulating the intestinal flora composition structure of mice and relieving ulcerative colitis.

The invention relates to an intelligent endoscope image evaluation method for ulcerative colitis, and the method comprises the steps: synchronously collecting video streams and three-dimensional point cloud data of a colonic mucosa through an endoscope system equipped with a structured light depth sensor, and constructing a three-dimensional coordinate system based on a colon anatomy trend; based on the three-dimensional point cloud data, constructing a complex topological structure on the surface of the colonic mucosa, and calculating a continuous homology feature set of the lesion area; and based on the persistent homology feature set, constructing a multi-scale graph neural network model of ulcerative colitis and Crohn disease specificity. By implementing the scheme, the structural and topological modeling of the colon mucosa lesion area can be realized, and the morphological characteristic difference between ulcerative colitis and Crohn's disease can be effectively captured. The multi-scale graph neural network fuses macroanatomical segmentation and micropathology features, efficient distinguishing of continuous and jumping lesions is achieved, finally, an intelligent and visual endoscope evaluation report is generated, and the accuracy and real-time performance of auxiliary diagnosis in an operation are improved.

The invention relates to the field of ulcerative colitis, and discloses a multi-parameter monitoring system for evaluating the intestinal barrier function of ulcerative colitis, which is used for realizing the goal of automatically adjusting a treatment scheme according to a monitoring result by constructing a closed-loop feedback treatment system. According to the invention, by designing the nanoprobe of which the surface is modified with a specific binding element and combining with a swallowing capsule endoscopy, real-time imaging and molecular level dynamic tracking of the intestinal barrier are realized, genetically engineered bacteria are constructed to quantify intestinal permeability abnormality and local inflammation level, and an intestinal barrier function damage score and a disease progress prediction result are output; individual monitoring is achieved through transfer learning, ultrasonic elastography, optical coherence tomography, wearable equipment for measuring intestinal electric field impedance spectroscopy and other technologies are adopted, an intestinal wall mechanics-electrophysiology composite parameter set is obtained, and the evaluation accuracy is improved.

The invention relates to a bifidobacterium animalis subsp. Lactis B7 as well as a composition and application thereof, and belongs to the technical field of microorganisms, the bifidobacterium animalis subsp. Lactis B7 is preserved in the China Center for Type Culture Collection on April 19, 2024, and the preservation number is CCTCC NO: M2024734. The bifidobacterium animalis subsp. Lactis B7 is named as Bifidobacterium animalis subsp. Lactis B7, the composition is named as Bifidobacterium animalis subsp. Lactis B7, and the composition is named as Bifidobacterium animalis subsp. Lactis B7. The invention also discloses application of the B7 fermentation composition in preparation of medicines for preventing and treating ulcerative colitis, constipation and constipation-type ulcerative colitis. According to the bifidobacterium animalis subsp. Lactis B7, high-yield short-chain fatty acid and indolepropionic acid are achieved, sulforaphane is generated through glucoraphanin, intestinal tract movement is improved, ulcerative colitis or inflammatory bowel disease activity index DAI and weight loss caused by the disease activity index DAI are effectively relieved, mouse colon injury is remarkably relieved, and mucosa layers are protected; the effects of resisting inflammation, inhibiting pathogenic bacteria and improving the intestinal barrier function are achieved.

The invention discloses a carrier-free nano-particle with pH / ROS dual response as well as a preparation method and application of the carrier-free nano-particle. The preparation method comprises the following steps: enabling quinolizidine alkaloid and flavonol to be subjected to self-assembly, so as to prepare quinolizidine alkaloid-flavonol carrier-free nano particles; modifying the quinolizidine alkaloid-flavonol carrier-free nano particles by adopting a phenylboronic acid-hyaluronic acid conjugate, so as to prepare nano particles modified by the phenylboronic acid-hyaluronic acid conjugate; and coating the surfaces of the nano-particles modified by the phenylboronic acid-hyaluronic acid conjugate with a pH sensitive polymer to prepare the pH / ROS dual-response carrier-free nano-particles. The sophocarpidine-kaempferol carrier-free nanoparticles with pH / ROS dual response, prepared by the invention, have the advantages of good targeting property, high biocompatibility, small toxicity and adverse reaction and the like, meanwhile, the nanoparticles have a good anti-inflammatory effect, and a new choice is provided for the treatment of ulcerative colitis.

The present invention relates to the technical field of probiotics, and in particular to a strain of Lactobacillus casei ZKLc1221, its lactobacillus and its application in improving ulcerative colitis. Lactobacillus casei )ZKLc1221 has been deposited in the General Microbiology Center of China Microorganism Culture Collection Committee on June 21, 2023, with the deposit address at No. 3, Yard No. 1, Beichen West Road, Chaoyang District, Beijing, and the deposit number is CGMCC No. 27673. The lactobacillus obtained by optimizing the fermentation conditions of Lactobacillus casei ZKLc1221 provided by the present invention has good thermal stability, good effect in improving ulcerative colitis, and can significantly improve pathological damage to the colon.

IL-23 binding proteins (e.g., antibodies) and methods of use, including methods of treating inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease) comprising administering IL-23 binding proteins.

The present invention discloses a black chicken liver hydrolyzed peptide that can be used to improve ulcerative colitis, and its preparation method and application, which belong to the field of biomedicine technology. The preparation method of the black chicken liver hydrolyzed peptide comprises the following steps: making black chicken liver into minced meat and mixing it with water, heating the obtained liquid material, adding alkaline protease for enzymatic hydrolysis, inactivating the enzyme and collecting the supernatant by centrifugation, and freeze-drying to obtain the black chicken liver hydrolyzed peptide. The present invention adopts formaldehyde titration to detect the degree of hydrolysis, adopts SDS-PAGE electrophoresis and Tricine-SDS-PAGE electrophoresis to detect the molecular weight, performs sequence analysis by LC-MS / MS, uses a database to predict the biological function of peptide segments, detects the antioxidant and blood pressure lowering ability of black chicken liver peptide by in vitro experiments, and detects the effect of black chicken liver peptide in improving colitis by mouse experiments. The results show that the black chicken liver peptide prepared by the present invention has the advantages of antioxidant, blood pressure lowering and improvement of ulcerative colitis.

The invention provides an Akkermann Amuc1100 protein mutant as well as a preparation method and application thereof, wild Akkermann Amuc1100 protein is subjected to mutation modification through a molecular biological technical means, and the bioactivity of the Amuc1100 protein mutant subjected to molecular modification is obviously improved compared with that of the wild protein; compared with a wild type Amuc1100 protein, the wild type Amuc1100 protein has a better effect when being applied to the aspects of regulating intestinal immunity, relieving acute pancreatitis, promoting browning of white adipose cells, inhibiting obesity, relieving ulcerative colitis and the like, and a very good application prospect is provided for developing bioactive medicines with higher efficiency.

The invention belongs to the technical field of drug delivery, and particularly relates to a multi-response colitis disease targeting hydrogel microsphere as well as a preparation method and application thereof. The hydrogel microsphere comprises a calcium ion cross-linked sodium alginate microsphere and HA-Cys / Cur NPs which is encapsulated in the calcium ion cross-linked sodium alginate microsphere, the preparation method comprises the following steps: self-assembling cysteine ethyl ester modified hyaluronic acid and curcumin to form nano-particles, encapsulating HA-Cys / Cur NPs into sodium alginate microspheres by an emulsification method, and carrying out calcium ion crosslinking, so as to obtain the hydrogel. The hydrogel microspheres have pH and GSH response characteristics and hyaluronic acid-mediated active targeting capability, are stable in a gastric acid environment, are accurately released at a colon part and target macrophages at an inflammation part, and NPs disconnects disulfide bonds and releases curcumin in an intracellular high GSH environment, so that synergistic treatment of anti-inflammation, anti-oxidation and intestinal mucosa repair is realized, and the curative effect is good. The medicine has a good application prospect in treatment of ulcerative colitis.

The invention belongs to the technical field of nano material synthesis, and particularly relates to baicalein-copper nano microgel as well as a preparation method and application thereof. According to the invention, copper ions and baicalein are coordinated to form nanowires, and the nanowires are coated with hyaluronic acid (HA) to prepare the nano microgel. The method is carried out at normal temperature, is simple in process and high in yield, and does not need toxic solvents; the obtained microgel has high stability (gastric acid resistance), targeted delivery (CD44 receptor mediation) and multiple biological activities (oxidation resistance and inflammation resistance). Animal experiments show that the pharmaceutical composition can significantly relieve ulcerative colitis, the dosage is as low as 5 mg / kg, the pharmaceutical composition is non-toxic, and a new strategy is provided for treatment of inflammatory diseases.

The invention discloses an anus medicine applying and applying device suitable for local treatment of ulcerative colitis, relates to the field of medical instruments, and solves the problem that an existing anus medicine applying device is difficult to operate. The anus medicine applying and applying device comprises a device shell and an injection tube installed at the end of the device shell, and a holding cylinder is arranged on the outer side of the device shell; a rubber piston is mounted on the inner side of the device shell in a sliding manner; the dosing mechanism is used for improving the medicine applying convenience of the injection tube, and the dosing mechanism is installed between the device shell and the holding cylinder; through the administration mechanism, a pushing rubber piston can be pushed to be arranged on the outer side of the device shell, so that an L-shaped structure is formed between the device shell and the holding cylinder, a patient can conveniently insert an injector into the anus with a single hand, the device is convenient for patients with more body types to use, the problem that a traditional medicine applying device is difficult to operate is solved, the pain of the patient in medicine applying is relieved, and the patient experience is improved. Therefore, the convenience of applying medicine to the anus is improved.

The invention provides assays and methods for analyzing inflammatory disorders of the gastrointestinal (GI) tract. Provided in embodiments of the invention are host transcriptome markers and classifiers amenable for assessing and monitoring the existence, severity and location of inflammation associated with inflammatory bowel disease (IBD), Crohn's disease (CD) and Ulcerative colitis (UC). Further provided are improved protocols for processing and analyzing fecal samples, providing superior non-invasive means for evaluating GI inflammation.

Provided herein are compositions comprising bacterial mixtures of strains from genera including Roseburia, Dorea, Bacteroides, Coprobacter, Agathobaculum, Lawsonibacter, Tyzzerella, Phascolarctobacterium, Enorma, Faecalimonas, lllomasclavelia, Clostridium, Fournierella, and / or Massilimicrobiota. Also provided are methods of using compositions comprising such bacterial mixtures. In some embodiments, it includes compositions, kits, and methods that are useful, e.g., for treatment and / or prevention of inflammatory bowel disease (IBD), such as ulcerative colitis (UC).

The invention discloses an establishment method and application of a damp-heat intestine accumulation type ulcerative colitis animal model, and belongs to the field of animal models.The establishment method comprises the steps that S1, high-fat feed treatment is conducted, specifically, experimental animals freely eat high-fat feed for 6-10 weeks from the first day; s2, DSS treatment: feeding 1.5% (w / v) DSS solution to the experimental animal for 2 weeks; and S3, observing the damp-heat syndrome type and ulcerative colitis related indications of the experimental animals, and selecting the experimental animals meeting the scoring standard, thereby establishing the ulcerative colitis mouse model. Aiming at the situation that most patients induce ulcerative colitis due to excess energy due to the change of dietary structures and lifestyles at present, the invention constructs and evaluates the damp-heat accumulation type ulcerative colitis mouse model by inducing internal dampness by a direct pathogenesis (high fat diet), which is closer to the actual situation of clinical patients. Therefore, a model and reference are provided for research and treatment of pathology of the damp-heat accumulation type ulcerative colitis and pharmacological mechanisms of traditional Chinese medicines.

The invention discloses stropharia rugoso-annulata polysaccharide as well as a preparation method and application thereof. The monosaccharide of the stropharia rugoso-annulata polysaccharide disclosed by the invention comprises glucose, galactose, mannose and galacturonic acid; the weight-average molecular weight of the stropharia rugoso-annulata polysaccharide is 1.4712 * 10 < 4 > to 1.623 * 10 < 4 > Da; the main chain of the stropharia rugoso-annulata polysaccharide contains-> 6)-alpha-D-(O-Me)-Galp-(1->, 1, 6-Glc, 1, 3-Man and 1.3-Gal exist in the main chain or a side chain, and terminal residues contain T-Glc and T-Gal. According to the invention, by constructing a DSS induced UC mouse model, the influence of Stropharia rugosoannulata polysaccharide (SRP1) on UC mice is investigated. Results show that the stropharia rugoso-annulata polysaccharide has a certain treatment effect on ulcerative colitis. In-vivo experiments show that the stropharia rugoso-annulata polysaccharide disclosed by the invention can increase abundance of bacteroides and thick-wall funguses and reduce abundance of proteobacteria and deferribacterium funguses; in-vitro experiments show that the stropharia rugoso-annulata polysaccharide can increase the abundance of beneficial bacteria bacteroides, reduce the abundance of harmful bacteria Escherichia-Shigella and Enterococcus, and increase the content of short-chain fatty acids.

The invention belongs to the field of microorganisms, and relates to lactobacillus paracasei. In particular discloses a lactobacillus paracasei strain HNGD-AL1, the taxonomic name is Lactobacillus paracasei, the lactobacillus paracasei strain HNGD-AL1 is preserved in China Center for Type Culture Collection on February 27, 2025, the preservation number is CCTCC M 2025303, and the preservation address is No. 299 on eight road in Wuchang District, Wuhan, Hubei. The method for degrading the sulfur-containing amino acid by adopting the lactobacillus paracasei is found for the first time, the effect of degrading 53.39% of the sulfur-containing amino acid can be achieved by culturing the probiotics in a fermentation culture medium for 24 hours, and the probiotics can be colonized in intestinal tracts and play a role in degrading the sulfur-containing amino acid in intestinal contents; the content of metabolite hydrogen sulfide of sulfur-containing amino acid in the intestinal tract is reduced by 60.92%, intestinal tract tissue damage, permeability and inflammatory response are reduced, and the purpose of improving ulcerative colitis is achieved. The preparation method has a wide application prospect in the aspects of preparation of low-sulfur-content amino acid foods and probiotic preparations for improving colitis.

The invention belongs to the field of compositions, and particularly relates to an anti-colitis composition and application, the anti-colitis composition comprises bacillus natto JLNA2301 bacterial liquid and ginseng water-soluble dietary fiber; the preservation number of the bacillus natto JLNA2301 is CGMCC (China General Microbiological Culture Collection Center) No. 27770; the volume mass ratio of the bacillus natto JLNA2301 bacterial liquid to the ginseng water-soluble dietary fibers in the composition is (8-10) mL: (0.25-1) g, and the viable count of the bacillus natto JLNA2301 bacterial liquid is 1 * 10 < 8 >-1 * 10 < 10 > CFU / mL; the composition can be used for preventing and treating colon shortening and bleeding caused by ulcerative colitis, repairing intestinal barrier protein and inhibiting a TLR4 / NF-kappa B inflammation pathway; the intestinal flora structure is regulated in a prevention period and a treatment period.

Disclosed herein in some embodiments are methods, compositions, and systems for distinguishing between ulcerative colitis (UC), Crohn's disease (CD) and other Inflammatory Bowel Disorders (IBD) by sequencing cell free nucleic acids. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether UC, CD, or other IBD are asymptomatic, in remission, or active. In some embodiments, microbial cell-free nucleic acid sequencing can provide data that can determine whether an active form of UC, CD, or other IBD is mild, moderate, or severe.

The invention relates to a system for evaluating the severity of an ulcerative colitis endoscope, and belongs to the technical field of medical systems. The system comprises a data acquisition module, a label calibration module, an ulcerative colitis endoscope severity evaluation model construction module, an ulcerative colitis endoscope severity evaluation model training module, an ulcerative colitis endoscope severity evaluation module and a second data acquisition module. A histological biopsy scoring and processing module; and a data processing and control module. The system provided by the invention can objectively evaluate the endoscopic disease activity of ulcerative colitis in real time and predict histological alleviation, can more accurately guide the formulation of a clinical treatment scheme, and is easy to popularize and apply.

The invention relates to the technical field of biological medicine, in particular to an ulcerative colitis disease clearance evaluation molecular marker and application thereof. By detecting the expression level of the HMGCS2 gene in a sample, the ulcerative colitis disease clearance state and disease activity period can be evaluated, and the method is used for curative effect monitoring, recurrence prediction and individualized treatment strategy formulation of ulcerative colitis and has important clinical application value and market prospect.

A Bifidobacterium longum subsp. longum dipro-017. The Bifidobacterium longum subsp. longum dipro-017 used has the ability to metabolize tryptophan to produce indole-3-lactic acid, can inhibit the pathogenic bacteria Salmonella Typhimurium, Staphylococcus aureus, and Escherichia coli, and can effectively mitigate weight loss caused by ulcerative colitis, improve a DAI score, improve colon length, mitigate the content of lipopolysaccharide (LPS) in blood, and increase the level of anti-inflammatory cytokine IL-10, as well as mitigate the content of bone metabolism indicators tartrate-resistant acid phosphatase (TRAP) and N-terminal propeptide of type I procollagen (PINP) in blood.

The invention belongs to the field of biological medicines, and particularly discloses application of uridine in preparation of medicines for preventing and treating ulcerative colitis, including application of uridine in preparation of medicines for preventing and treating ulcerative colitis in acute stage, application of uridine in preparation of medicines for preventing and treating ulcerative colitis in remission stage and the like. Uridine can improve the symptoms of DSS-induced acute experimental colitis model mice, has a good treatment effect, and improves the weight of the model mice; experimental results indicate that a high-dose group of uridine has a good treatment effect, the mechanism and specificity of uridine up-regulate expression and activity of colon local SIRT1 protein, further inhibit phosphorylation activation of an NF-kappa B signal channel, regulate secretion of inflammatory factors and expression of tight junction protein, repair intestinal mucosal barrier while moderately regulating immunity, and improve the immunity of a human body. The systemic inflammatory response is effectively relieved.

The invention relates to the field of new application of traditional Chinese medicinal materials, and particularly provides application of ash grass root in preparation of medicine for treating ulcerative colitis, DSS-induced mouse colitis model experiments and UC patient control experiments show that ash grass root has remarkable technical effects in treatment of ulcerative colitis, and the application of ash grass root in preparation of medicine for treating ulcerative colitis in preparation of medicine for treating ulcerative colitis in preparation of medicine for treating ulcerative colitis. The gray couchgrass root shows the effect of relieving inflammatory response, tissue damage and immune disorder related to colitis; the intestinal mucosa repair is promoted; the intestinal barrier function is strengthened; the pathological state of colon tissue is improved; the level of inflammatory factors is reduced; and flora metabolism can be adjusted. The invention provides a new natural medicine source for preventing and treating ulcerative colitis, and has good application value and industrial transformation prospect.

The invention discloses application of copper-amino acid nano enzyme in preparation of anti-inflammatory drugs, and relates to the technical field of biomedical new materials, amino acids comprise glycine, arginine, histidine, threonine, phenylalanine and cysteine; the ratio of the amino acid to the copper ions is 1: (0.5-5), and the synthesis temperature of the copper-cysteine nano enzyme is 25-125 DEG C. The copper-amino acid nano-enzyme library established by the invention has efficient hydroxyl free radical, superoxide free radical and hydrogen peroxide scavenging activity; wherein the copper-cysteine nano-enzyme shows the highest enzymatic activity, and shows low toxicity and good biocompatibility in both the cell level and the animal level; meanwhile, the copper-cysteine nano-enzyme also shows anti-inflammatory activity and anti-oxidative stress activity, can remarkably improve cell inflammation and body inflammation, relieves and treats dextran sodium sulfate induced mouse ulcerative colitis, and can be further applied to preparation of drugs for treating inflammatory bowel diseases.

The invention discloses an ulcerative colitis image classification method based on a multi-scale attention fusion network, belongs to the technical field of image information mining and classification, and combines a staged feature extraction backbone network, a multi-scale attention fusion module (SCHL) and a classification module. The ulcerative colitis lesion image classification method has the advantages that significant advantages are shown in ulcerative colitis lesion image automatic classification tasks, an OfficientNet backbone network has staged feature extraction capacity, multi-level information from shallow texture to deep semantics in lesion images can be effectively captured, an SCHL module performs modeling by fusing channel attention, space attention and level high-frequency information, and the ulcerative colitis lesion image classification efficiency is improved. The model is guided to focus on a key lesion area, background interference is inhibited, feature discrimination is enhanced, the recognition ability of the model to a fine-grained lesion form and the generalization ability of the model to a complex clinical image are remarkably improved, and higher accuracy and robustness are achieved in refined classification of ulcerative colitis.

The invention relates to construction of an oral drug-loading nano-structure lipid carrier with double-targeting design and application of the oral drug-loading nano-structure lipid carrier in treatment of ulcerative colitis, the oral drug-loading nano-structure lipid carrier comprises solid liposome, liquid liposome and active substances, and the active substances are entrapped in a lipid layer formed by the solid liposome and the liquid liposome. The dual-targeting nano-structure liposome can effectively improve the solubility of the drug, target colon and inflammatory tissues, improve the curative effect and reduce the dosage of the drug.

The invention discloses anti-inflammatory polypeptide nanoparticles and a preparation method thereof, and belongs to the technical field of bioactive peptides. The anti-inflammatory polypeptide nano-particles are nano-particles obtained by coating polypeptide with an anti-inflammatory effect with chitosan and sodium tripolyphosphate, the polypeptide with the anti-inflammatory effect contains bioactive peptides of which the amino acid sequences are YAADQ, FPYTT and YVTYA. The phycocyanin anti-inflammatory peptide is natural in source, the performance of the phycocyanin anti-inflammatory peptide can be remarkably improved through the nanometer embedding technology, and compared with traditional drugs, the phycocyanin anti-inflammatory peptide has lower toxic and side effects and potential cost advantages. The polypeptide nanoparticles prepared by the invention can effectively prevent the phycocyanin anti-inflammatory peptide from being degraded in the digestive tract, have a remarkable treatment effect on mice with ulcerative colitis, and have an important application prospect in preparation of ulcerative colitis prevention and treatment products.

The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to application of Xianglian intestine decoction in preparation of a medicine for treating ulcerative colitis through a targeted TLR4 / NLRP3 / GSDMD channel. According to the invention, the TLR4 is determined as a key target, and experiments show that the active ingredients in the Xianglian intestine soup and the TLR4 have very strong binding affinity. In-vivo experiments prove that the Xianglian intestine soup down regulates the protein levels of TLR4, NLRP3 and GSDMD-N and the mRNA expression (Plt; 0.05) of IL-1beta and IL-18, so that the pyroptosis is inhibited. Furthermore, the Xianglian intestine decoction inhibits NLRP3 inflammasome activation and GSDMD-mediated pyroptosis by targeting TLR4 so as to relieve UC inflammation and intestinal barrier injury. The invention provides a mechanism insight for the clinical curative effect of the Xianglian intestine decoction for treating ulcerative colitis.